Skip to main content
OpenTrials
Completed

NCT Number: NCT04033211

NOVOsyn® for Trocar Incision After Laparoscopic Appendectomy and Cholecystectomy

The aim of this study is to evaluate if the application of a Chlorhexidine coated suture (Novosyn® CHD) will reduce the colonization of bacteria in comparison to an uncoated suture (Novosyn®) used for the closure of trocar wounds in laparoscopic surgery (appendectomy and cholecystectomy).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Klinikverbund Südwest Krankenhaus Leonberg Alllgemeinchirurgie, Leonberg, Baden-Wurttemberg, Germany

Loading trial locations.

About this study

The bacteriostatic and bactericidal effect of Novosyn® CHD will be assessed by the incidence of surgical site infection (SSI) in each suture group until 30 days postoperatively. The frequency of infections (SSI: A1 and A2) is considered as a suitable parameter for the assessment of efficacy. It is expected that the use of the Novosyn® CHD suture will reduce the occurrence of infections (SSI: A1 and A2) 30 days postoperatively compared to Novosyn suture (primary objective). SSI will be classified according to the Centre of Disease Control and Prevention (CDC), therefore the time point for assessment of SSI as set to 30 days postoperatively.

Furthermore, short-term and long-term complications, the handling of the suture material, length of postoperative hospital stay, costs, pain, quality of life, time to return to work, hernia rate including umbilical hernias and the cosmetic outcome will also be assessed as secondary objectives.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or cholecystectomy.
  • Written informed consent
  • Age≥ 18 years
  • Not incapacitated patient

Exclusion criteria

  • Open surgery for appendectomy or cholecystectomy
  • Pregnancy
  • Allergy or hypersensitivity to chlorhexidine
  • Intraoperatively conversion from laparoscopic to open surgery
  • Patients taking medical consumption that might affect wound healing

Treatment and study plan

Novosyn® CHD for fascia and skin closure

Device

Experimental

Novosyn® for fascia and skin closure

Device

Comparator

Primary outcomes

  1. Surgical Site Infection

    Time frame: until 30 days + 10 days after surgery

    Incidence of postoperative surgical site infections, SSI (A1: Superficial incisional site infections and A2: Deep incisional surgical site infections) (efficacy parameter) Surgical Site Infection (SSI) is defined according to the definition of the US Centres for Disease Control and Prevention (CDC).

Secondary outcomes

  1. Development of Wound Dehiscence

    Time frame: until discharge (ca. 10 days postop), 30 days +10 days and 1 year ±2 months postoperatively

    Incidence of wound dehiscence (skin) at different postoperative examinations

  2. Reoperation Rate

    Time frame: until discharge (ca. 10 days postop), 30 days +10 days and 1 year ±2 months postoperatively

    Incidence of reoperation rate at different postoperative times

  3. Mortality Rate

    Time frame: until discharge (ca. 10 days postop), 30 days +10 days, and 1 year ±2 months postoperatively

    Incidence of mortality rate at different postoperative times

  4. Postoperative Complications during the postoperative Course

    Time frame: until discharge (ca. 10 days postop), 30 days +10 days, 1 year ±2 months postoperatively

    Rates of postoperative complications such as bleeding, tissue reaction, abscess, perforation, bile leaks, biliary peritonitis, ileus, stenosis, fistula at different postoperative points in time

  5. Suture Removal due to Wound Problems during the postoperative Course

    Time frame: until discharge (ca. 10 days postop), 30 days +10 days, and 1 year ±2 months postoperatively

    Rate of suture removal due to wound problems (infection, dehiscence, residual material requiring removal) at different defined postoperative points in time

  6. Length of hospital stay

    Time frame: until discharge (ca. 10 days postop)

    Defined as the time period from day of operation until day of discharge (efficacy parameter).

  7. Postoperative Surgical Site Infections

    Time frame: 1 year ±2 months post-op

    Incidence of postoperative surgical site infections

  8. Rate of Conversion to open surgery

    Time frame: intraoperatively

    Number of interventions where operation technique has to be converted to open surgery intraoperatively

  9. Time to return to work

    Time frame: up to 1 year ±2 months

    Defined as the duration (days) from day of surgery until the day when the patient was able to work. Employment status of the patient will also be reported.

  10. Course of Pain: Visual Analogue Scale (VAS)

    Time frame: preoperatively, at day of discharge (ca. 10 days postop), at 30 days +10 days and 1 year ±2 months postoperatively

    This parameter will be noted using the Visual Analogue Scale (VAS) which state "0" at one end representing "no pain" and "100" at the opposite end representing "maximal pain". The values are compared over postoperative period.

  11. Course of Cosmetic result

    Time frame: 30 days +10 days, 1 year ±2 months postoperatively

    Overall patient and observer satisfaction with the scar using the Patient and Observer Scar Assessment Scale (POSAS). Cosmetic result and the scar will be evaluated by the patient and the physician. Patient will rate the cosmetic outcome in six categories (Pain, Itching, Color of scar, Stiffness of scar, thickness and irregularity of scar) on a 1 to 10 points scale each. The physician will use the Observer component, rating vascularization, pigmentation, thickness, relief and pliability of the scar on a 1 to 10 points scale each. The categories are added to a total POSAS score of 11 (minimum) to 110 points (maximum)

  12. Course of Overall patient and observer satisfaction with the scar: Patient and Observer Scar Assessment Scale (POSAS)

    Time frame: 30 days +10 day, 1 year ±2 months postoperatively

    Overall patient and observer satisfaction with the scar using the Patient and Observer Scar Assessment Scale (POSAS). Cosmetic result and the scar will be evaluated by the patient and the physician. Patient will rate the cosmetic outcome in six categories (Pain, Itching, Color of scar, Stiffness of scar, thickness and irregularity of scar) on a 1 to 10 points scale each. The physician will use the Observer component, rating vascularization, pigmentation, thickness, relief and pliability of the scar on a 1 to 10 points scale each. The categories are added to a total POSAS score of 11 (minimum) to 110 points (maximum)

  13. Comparison of wound appearance

    Time frame: discharge (ca. 10 days postop), 30 days +10 days and 1 year ±2 months postoperatively

    Photographic documentation of the wounds for assessment

  14. Comparison of handling parameters of the suture materials

    Time frame: intraoperatively

    Comparison of the handling features of the suture materials in eight different categories (ease of passage of the suture, first throw knot holding, knot tie down smoothness, knot security, surgical hand, memory effect, lack of frying and the overall handling) by rating each category on a 5 point scale (excellent, very good, good, satisfied, poor); no overall score is calculated, the categories are compared separately

  15. Course of Health Status

    Time frame: 30 days +10 days after surgery, 1 year ±2 months after surgery

    EQ-5D is a standardised measure of health status developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D is designed for self-completion by respondents and it takes only a few minutes to complete. Instructions to respondents are included in the questionnaire. EQ-5D-5L consists of 2 pages - descriptive system and the EQ visual Analogue scale (EQ-VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the respondents self rated health on a 20 cm vertical , visual analogue scale with endpoints labelled "the best health you can imagine" and " the worst health you can imagine"

  16. Hernia Rate / Umbilical Hernia Rate

    Time frame: until discharge (ca. 10 days postop), 30 days +10 days, 1 year ±2 months postoperatively

    Hernia rate including umbilical hernia postoperatively verified by ultra-sound examination compared at different postoperative points in time

  17. Costs (economics)

    Time frame: 1 year ±2 months

    Assessment of costs will be calculated on postoperative complication (SSI) in both suture groups (efficient parameter).

Sponsors and collaborators

Lead sponsor

Aesculap AG

Industry

Collaborators

  • B.Braun Surgical SA

Registry information

Official study title

Randomized, Multi-center, Double Blinded, Prospective Study to Evaluate the Incidence of Complications in Laparoscopic Cholecystectomy and Appendectomy Using Novosyn® CHD Versus Novosyn® Suture Material to Close Trocar Wound

Acronym: NOVOTILAC

Important dates

Study start
2020
Primary completion
2022
Study completion
2023
First posted
Jul 26, 2019
Registry last updated
Jun 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.